Publication
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Joseph P McGuirk, Armin Ghobadi, Carlos R Bachier, Paul J Shaughnessy, Farrukh Awan, Joseph E Maakaron, Michael R Bishop, P Joy Ho, Constantine S Tam, Michael Dickinson, Justin M Darrah, Edmund K Waller, Hemant S Murthy, Ainsley Ross, Leah M Williams, Chenyi Pan, William N Stevens, Laura Serwer, Thao Nguyen, Jonathan Terrett, Demetrios Kalaitzidis, Anna Ma, Huansheng Xu, Mark Benton, Annie Weaver, Sarah Beaussant Cohen, Richard T Maziarz, Chan Cheah
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric antigen receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard…
Read on PubMedLinked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04035434registry_reference1.00
Candidate 2
- cancerHodgkin Lymphomadictionary0.60
- cancerNon-Hodgkin Lymphomadictionary0.60
Registered trialsNCT04035434
Curated evidence
Evidence citing this paper (0)
Data not yet available